Kromek Share Price (KMK)

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Kromek Group Plc LSE:KMK London Ordinary Share GB00BD7V5D43 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.10 -0.63% 15.80 681,643 16:35:18
Bid Price Offer Price High Price Low Price Open Price
15.80 16.30 16.15 15.75 16.15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.12 -18.35 -4.80 68
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:18 UT 1,250 15.80 GBX
Related Shares
Astrazeneca (AZN), Glaxosmithkline (GSK), Motif Bio (MTFB), Bermele (BERM)

Kromek (KMK) Latest News

Kromek News

Date Time Source Headline
09/3/202113:34ALNCIN BRIEF: Kromek wins nuclear detection contract worth USD960,000
09/3/202107:00UKREGKromek Group PLC Kromek awarded Nuclear Detection contract
04/3/202113:32UKREGKromek Group PLC Holding(s) in Company
02/3/202108:30UKREGKromek Group PLC PDMR Dealings
01/3/202115:34ALNCTRADING UPDATES: 1Spatial expects full-year results ahead of forecasts
01/3/202114:53UKREGKromek Group PLC Results of Placing, Open Offer and General Meeting
01/3/202107:00UKREGKromek Group PLC New Medical Screening and Nuclear Security orders
19/2/202114:06UKREGKromek Group PLC Second Price Monitoring Extn
19/2/202114:01UKREGKromek Group PLC Price Monitoring Extension
15/2/202107:00UKREGKromek Group PLC Posting of Circular
More Kromek News
Kromek Investors    Kromek Takeover Rumours

Kromek (KMK) Discussions and Chat

Kromek Forums and Chat

Date Time Title Posts
07/4/202118:58Kromek Group PLC4,248
21/8/201710:01Kromek Group (KMK) - Overvalued AIM mugging181

Add a New Thread

Kromek (KMK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-04-12 15:35:1815.801,250197.50UT
2021-04-12 15:12:1116.1510,0001,614.98O
2021-04-12 14:40:2415.8650,1857,956.83O
2021-04-12 14:31:0515.9010,0001,590.00O
2021-04-12 14:03:3915.9215,3912,450.25O
View all Kromek trades in real-time

Kromek (KMK) Top Chat Posts

DateSubject
12/4/2021
09:20		Kromek Daily Update: Kromek Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker KMK. The last closing price for Kromek was 15.90p.
Kromek Group Plc has a 4 week average price of 15.03p and a 12 week average price of 15.03p.
The 1 year high share price is 27.25p while the 1 year low share price is currently 7.80p.
There are currently 431,851,820 shares in issue and the average daily traded volume is 997,592 shares. The market capitalisation of Kromek Group Plc is £68,232,587.56.
Read Full Thread
Reply
05/4/2021
12:39		aqc888: I agree, the huge share price swings illustrate that people are unsure what to make of Kromek. I’m a bit sceptical about this biological pathogen detector. But Kromek do make cutting edge equipment in other areas so have track record of delivering market leading equipment. I just can’t get my head around why the media who's main story at the moment is the pandemic, haven’t picked up on this story. Also why haven’t airline executives/cruise companies etc been talking up this device to boost confidence in their own companies. Whilst I trust Simon Thompson’s research, it just doesn’t all seem to add up. I get some comfort from seeing how long the delay was to Moderna and BATMs share prices to rise, despite their progress with profitable products related to the pandemic, and hope the same is true of Kromek. I’m hoping that the CEO with his mainly science background (evidence based) might be waiting to see what the evidence of the devices performance is before screaming from the rooftops. I’m also a bit concerned that there is no director buying. (BATM directors made big purchases when the share price remained low) which encouraged me to increase my holding. With Kromek it seems like alot of faith in Simon Thompson and the word of the CEO are required. But even if the pathogen detector doesn’t work out, it’s still a company with a lot of other products. So hopefully not too much downside risk, but huge upside potential with an analyst from Simon Thompson’s article suggesting x2 years profit from Kromeks pathogen machine could be equal to Kromeks current market capitalisation. I think with a bit of tangible credibility behind this pathogen detector the share price will start rising
Read Full Thread
Follow
Reply
28/3/2021
21:02		aqc888: Just been looking at the Moderna share price to see how the market reacted to the most promising vaccine company at the beginning of the pandemic and it was pretty slow. Not comparable to Kromek I know, but I make the comparison as it’s a company that similarly was creating a solution to an unknown unresearched situation. Like Kromek. Moderna share price in the year pre pandemic 12-27c. Date pandemic officially declared 21.3c. 1month into pandemic 33c, 2months into pandemic 66c, upto a peak of 148c last month.
Read Full Thread
Follow
Reply
28/3/2021
20:37		aqc888: I’m still hanging on to Kromek though despite my worries. It appears to be a good company with a few ‘strong buy’ recommendations from Simon Thompson. Last ‘strong buy’ I followed ST on was sylvanian platinum which surged big time. This alluring wild card of the biological pathogen detector that’s thrown in for free within the Kromek share price makes this share a speculative buy backed up by a fairly solid company that continually has had bad luck in my opinion. I just can’t quite understand why they haven’t sold these in advanced to airlines & airports. Imagine sitting at the gate waiting to board your plane and one of these machines is monitoring the air so every flight is ‘covid secure’ like an extra security measure. You’d think such a device before boarding every plane destined for the UK would make the risk of mutant strains entering the uk far far lower. 1/800,000 as Simon Thompson reported. Perhaps Kromek don’t want to step on the toes of OEM suppliers to airports (who are their clients) or perhaps airlines don’t want the havoc positive covid tests would case to their schedules. If a positive covid case was detected by the machine at the boarding gate, the airline wouldn’t know who was positive and they might be liable to getting sued if they didn’t cancel the flight. So they might not want these devices as the cost of alerts could be huge. All pure speculation, but if this type of machine (and the Kromek one seems to be the market leader) becomes an essential piece of kit in just one these settings (hospitals, care homes, gp surgeries, schools, shopping malls, offices, airports) the Kromek share price will go absolutely nuts and blow away analyst Paul Hills global market estimate of £500m. Remember they have been scaling up their production capabilities lately so could be well placed to manufacture (as well as license their invention to other manufacturers) and exploit the market to huge gains. I’m holding on and think I just persuaded myself to top up my holding!
Read Full Thread
Follow
Reply
21/3/2021
19:05		b00mb0y: I’ve been averaging down for many years now. A couple of times I could have sold and taken a profit but didn’t. I could have sold end of jan / start of feb with an 8k profit but didn’t. More fool me. My average is .2089p so I’m down again on paper. ST has always wrote highly of Kmk and he strongly believes in them. I’m expecting another of his write ups pretty soon and hope that pushes the share price higher. I am of the belief that Kmk will come good. But when? How much longer? How long is a piece of string? Hopefully before any of the other players get their products to market. Come on Kmk. Pull your finger out.
Read Full Thread
Follow
Reply
17/3/2021
10:13		b00mb0y: all those reviews are all well and good and makes you sit up and think of what could really happen if...... However, KMK is a small company, albeit with what we believe to be excellent pathogen detectors, radiation etc, but they need to get their products to market before one of the many, many other bigger companies does. Otherwise this share price will be back to single figures before you can cough. This share price is dwindling on a daily basis and its becoming the trend of years of small spikes followed by the dwindle.
Read Full Thread
Follow
Reply
15/3/2021
13:11		varies: As we all know, news can be bad as well as good but at least KMK is unlikely to be seeking any more money from us for another year or two. If KMK had been able to make the deliveries in China of goods actually in warehouses out there ready to be delivered to the customers, so we are told, as soon as the right KMK personnel are let into the country, then the £13 million price of these goods would presumably have been paid to KMK and there would have been no need for the recent Open Offer. Is there some doubt about receiving this £13 million ? We are assured that there is not but it seems likely that KMK's bank was unwilling to advance money secured on it. This is an important imponderable. Another imponderable is obviously the rate of sales of our various ingenious products. They all sound wonderful but what is the demand for them ? I am inveterate optimist and inclined to add at the current price.
Read Full Thread
Follow
Reply
13/2/2021
11:18		dougmachin: A few more thoughts: [1] If Dr Arnab Basu wasn't able to sell snow in snowy places, then this company may have folded a long time ago. Along with everyone's money. With the technology bought for peanuts by waiting vultures. I can only sympathize with the frustrations of long term holders, but maybe this time, with 10 million worth of additional institutional pressure, he realizes it's now (this time) or never. [2] Somehow that rise, again I feel on very little new news, was a real stroke of luck. Had that not happened, he wouldn't have been able to go to institutions to say, "I'm giving you a 23% discount". He took advantage of the spike and acted on it. Of course, if institutions don't step-up, then this share is dead in the water, but if they do step-up, then for me this is exciting times ahead. 10 million worth of extra institutional belief will result in a real strengthening of the share price from this 16p point. [3] It must be really difficult doing the kind of manufacturing that KMK is doing. This is the kind of thing that Universities do for years, with backing that keeps going. I imagine Universities are more likely to receive continued funding compared to having to do the research whilst making a profit, which is what KMK is trying to do. KMK are building the research facilities, doing the research, then building the products, which are all so state of the art, people aren't sure whether they need them or not. I am sorry for holders of the past 8 years, but as I watch and if / when institutions start taking up this 10 million, I shall be more and more likely to buy more. This is a risk. It may take time, but hopefully not so long any more, and the upside here is tremendous!!!
Read Full Thread
Follow
Reply
25/11/2020
20:57		b00mb0y: All this sounds good for KMK. However, according to walletinvester.com KMK’s share price will drop to .06157 in 12 month and possibly crash. Check out the above website for the information / view they give on KMK. I’ve been invested in KMK since it’s IPO only to watch it dwindle to this sad share price figure. WTF is going to get this share price back up to give us a MC over £100m again. Getting well pi55ed off now!
Read Full Thread
Follow
Reply
03/11/2020
14:26		sev22: I am highlighting this article, published by Simon Thompson on the 7th October 2020, just to reassure those who are still invested here. If anything the news flow has improved since this update so I am surprised to see so many investors bailing out. Kromek (KMK:8p), a Sedgefield-based radiation detection technology company focused on the medical, security screening and nuclear markets, has announced annual results today. The Covid-19 impact on the business led to Kromek reporting an underlying cash loss of £400,000 on 9 per cent lower revenue of £13.1m. This had already been flagged at the time of the pre-close trading update from the £27.5m market capitalisation company (‘Stock picking value open to future gains’, 4 May 2020). Of far more interest is Kromek’s subsequent $5.2m (£4m) contract extension by the Defence Advanced Research Projects Agency (DARPA), an agency of the US Department of Defence, for work on developing a mobile bio-security system capable of detecting airborne pathogens. That’s because the project is now expected to be expanded for use in the non-military sector in response to the outbreak of Covid-19. Kromek has already developed a prototype to sample air and identify the presence of any biological pathogen – including Covid-19 or any mutant version that may emerge over time. The technology can be used to immediately flag the presence of someone with a contagious disease and allow effective mitigation of the risk of transmission. By placing samplers in high footfall areas, such as airports and hospitals, or where people are in close proximity for long periods, threats can be identified without having to individually test people. Knowing a carrier is infected with a disease before they infect further individuals is key to halting the onset of an outbreak and before it causes major global disruption. Non-military applications include use in shopping centres, sports arenas, theme parks, schools, hospitals, offices, airplanes, and cruise ships. Importantly, it’s incredibly accurate, giving a false alarm in just one in 800,000 tests. Chief executive Arnab Basu revealed during this morning’s results call that Kromek will undertake field trials with the pre-production prototype collecting airborne samples from urban and rural locations starting in January, and has field tests scheduled in London with two UK government agencies: The Defence Science and Technology Laboratory (DSTL), an executive agency of the Ministry of Defence; and Defence Aviation Repair Agency (DARA). Kromek also plans for delivery of units for pilot deployment in the US in the first half of 2021. It could be a saviour for the UK government given the problems it’s facing with its much maligned Covid-19 test and trace programme. It could also reverse the fortunes for shareholders who have seen the share price decline since hitting a 12-month high of 27p in May, losing two-thirds of its value and taking the price well below the 17.5p level of my repeat buy call in early May. Share price decline The major reason for today’s share price fall is that Kromek unexpectedly revealed a £13.1m write-down on a medical imaging contract due to Covid-19 which has disrupted both the shipment to hospitals and access onsite. Work in progress had been stockpiled for delivery and recognised as revenue over the course of the past 30 months. With shipment originally scheduled for 2020 onwards now delayed, the carrying value of accounts receivable under contract (AROC) is dependent on Kromek being able to prove a shipping date. It is unable to provide this at present, hence the £13.1m write-down to AROC in the accounts. However, all the stock remains on Kromek's balance sheet (and in its UK facilities) ready for shipment and delivery in the future, hence why the directors still expect the position to reverse, at which point Kromek can book a hefty exceptional credit. I am not sure investors have fully grasped this accounting point. Kromek’s rebound potential I am not sure they have grasped that a rebound in the 2020/21 financial year is on the cards either. Firstly, Kromek has now started delivering on a delayed seven-year Original Equipment Manufacturer (OEM) contract worth US$58m (£45m) to provide its cutting edge CZT detectors and advanced electronics in state-of-the-art medical imaging detectors. The contract should deliver revenues worth “millions of dollars” in the current financial year, says Mr Basu. The same is true of another delayed contract from the 2019/20 financial year. Secondly, the company continues to win new contracts in other parts of the business. Kromek was awarded $1.1m worth of contracts to add technical innovation capability to its D3S ‘dirty bomb detectors’ by US government agencies. They are proving popular in Europe, too, with the European Commission and Irish Civil Defence also using them. Given the heightened terrorism risk across the world, the 22 countries currently deploying the technology is likely to grow. Thirdly, Mr Basu reassuringly notes that Kromek’s revenue is now back to pre-Covid-19 levels following the disruption of the first quarter to 31 July 2020. That’s important as it means that concerns over the company’s cash position should now ease, another reason for the share price fall since May. Finance director Derek Bulmer says that the company had gross cash of £9.4m at 30 April 2020 and gross debt of £5.6m. Since then it has strengthened its gross cash reserves by over £2m and varied bank covenants on its HSBC facility. Given that revenue has returned to pre-Covid-19 levels, and stocks are now being delivered on delayed contracts, the company should have the funding in place to operate without the need to tap shareholders. This may not have been made clear to investors. The bottom line is that the 40 per cent share price discount to net asset value of 13p should reverse when investors cotton onto the huge commercial opportunities for Kromek's ground breaking DARPA airborne pathogens technology that is being piloted. Strong Buy.
Read Full Thread
Follow
Reply
07/10/2020
12:05		sev22: A Simon Thompson update 'hot off the press' issued at mid-day today. A Tech winner in fight against Covid-19. Kromek (KMK:8p), a Sedgefield-based radiation detection technology company focused on the medical, security screening and nuclear markets, has announced annual results today. The Covid-19 impact on the business led to Kromek reporting an underlying cash loss of £400,000 on 9 per cent lower revenue of £13.1m. This had already been flagged at the time of the pre-close trading update from the £27.5m market capitalisation company (‘Stock picking value open to future gains’, 4 May 2020). Of far more interest is Kromek’s subsequent $5.2m (£4m) contract extension by the Defence Advanced Research Projects Agency (DARPA), an agency of the US Department of Defence, for work on developing a mobile bio-security system capable of detecting airborne pathogens. That’s because the project is now expected to be expanded for use in the non-military sector in response to the outbreak of Covid-19. Kromek has already developed a prototype to sample air and identify the presence of any biological pathogen – including Covid-19 or any mutant version that may emerge over time. The technology can be used to immediately flag the presence of someone with a contagious disease and allow effective mitigation of the risk of transmission. By placing samplers in high footfall areas, such as airports and hospitals, or where people are in close proximity for long periods, threats can be identified without having to individually test people. Knowing a carrier is infected with a disease before they infect further individuals is key to halting the onset of an outbreak and before it causes major global disruption. Non-military applications include use in shopping centres, sports arenas, theme parks, schools, hospitals, offices, airplanes, and cruise ships. Importantly, it’s incredibly accurate, giving a false alarm in just one in 800,000 tests. Chief executive Arnab Basu revealed during this morning’s results call that Kromek will undertake field trials with the pre-production prototype collecting airborne samples from urban and rural locations starting in January, and has field tests scheduled in London with two UK government agencies: The Defence Science and Technology Laboratory (DSTL), an executive agency of the Ministry of Defence; and Defence Aviation Repair Agency (DARA). Kromek also plans for delivery of units for pilot deployment in the US in the first half of 2021. It could be a saviour for the UK government given the problems it’s facing with its much maligned Covid-19 test and trace programme. It could also reverse the fortunes for shareholders who have seen the share price decline since hitting a 12-month high of 27p in May, losing two-thirds of its value and taking the price well below the 17.5p level of my repeat buy call in early May. Share price decline The major reason for today’s share price fall is that Kromek unexpectedly revealed a £13.1m write-down on a medical imaging contract due to Covid-19 which has disrupted both the shipment to hospitals and access onsite. Work in progress had been stockpiled for delivery and recognised as revenue over the course of the past 30 months. With shipment originally scheduled for 2020 onwards now delayed, the carrying value of accounts receivable under contract (AROC) is dependent on Kromek being able to prove a shipping date. It is unable to provide this at present, hence the £13.1m write-down to AROC in the accounts. However, all the stock remains on Kromek's balance sheet (and in its UK facilities) ready for shipment and delivery in the future, hence why the directors still expect the position to reverse, at which point Kromek can book a hefty exceptional credit. I am not sure investors have fully grasped this accounting point. Kromek’s rebound potential I am not sure they have grasped that a rebound in the 2020/21 financial year is on the cards either. Firstly, Kromek has now started delivering on a delayed seven-year Original Equipment Manufacturer (OEM) contract worth US$58m (£45m) to provide its cutting edge CZT detectors and advanced electronics in state-of-the-art medical imaging detectors. The contract should deliver revenues worth “millions of dollars” in the current financial year, says Mr Basu. The same is true of another delayed contract from the 2019/20 financial year. Secondly, the company continues to win new contracts in other parts of the business. Kromek was awarded $1.1m worth of contracts to add technical innovation capability to its D3S ‘dirty bomb detectors’ by US government agencies. They are proving popular in Europe, too, with the European Commission and Irish Civil Defence also using them. Given the heightened terrorism risk across the world, the 22 countries currently deploying the technology is likely to grow. Thirdly, Mr Basu reassuringly notes that Kromek’s revenue is now back to pre-Covid-19 levels following the disruption of the first quarter to 31 July 2020. That’s important as it means that concerns over the company’s cash position should now ease, another reason for the share price fall since May. Finance director Derek Bulmer says that the company had gross cash of £9.4m at 30 April 2020 and gross debt of £5.6m. Since then it has strengthened its gross cash reserves by over £2m and varied bank covenants on its HSBC facility. Given that revenue has returned to pre-Covid-19 levels, and stocks are now being delivered on delayed contracts, the company should have the funding in place to operate without the need to tap shareholders. This may not have been made clear to investors. The bottom line is that the 40 per cent share price discount to net asset value of 13p should reverse when investors cotton onto the huge commercial opportunities for Kromek's ground breaking DARPA airborne pathogens technology that is being piloted. Buy.
Read Full Thread
Follow
Reply
Kromek share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
KMK
Kromek
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210412 23:53:28